Talis Biomedical announced that it has appointed Dr. Andrew Lukowiak as president and chief scientific officer, effective August 1, 2023. Dr. Lukowiak joins Talis Biomedical from Epigenomics AG where he served as president and chief scientific officer and developed the next generation of its blood-based colorectal cancer screening test.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TLIS:
- Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023
- Talis Biomedical announces new data on CT/NG/TV multiplex test
- Talis Biomedical regains compliance with Nasdaq minimum bid price requirement
- Talis Biomedical Announces 1-for-15 Reverse Stock Split
- Talis Biomedical announces 1-or-15 reverse stock split
